{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:34:33Z","timestamp":1759160073900,"version":"3.44.0"},"reference-count":26,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,8,18]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>We report a case of a female in her mid-40s diagnosed as norethisterone-induced liver injury. Our patient presented to the medical gastroenterology clinic with an incidental finding of progressively increasing transaminases. A detailed evaluation strongly supported our suspicion of progestin-induced liver disease with prompt reversal after discontinuation of norethisterone. Various clinical trials on the safety and efficacy of norethisterone suggest that liver injury is not a common adverse event associated with norethisterone use. Oestrogens are more commonly, and progestogens are less frequently,associated with a spectrum of liver abnormalities, including hepatocellular or cholestatic types of injury, peliosis hepatitis and sinusoidal obstruction syndrome. It may be a completely incidental finding, as in our patient. Our patient lacks cardiometabolic risk factors such as obesity, diabetes mellitus and dyslipidaemia, which are typically associated with metabolic dysfunction-associated steatotic liver disease (MASLD), or alcohol use. Awareness of rare adverse drug reactions, as in this case with norethisterone, is vital for prompt diagnosis and effective management and hence prevention of potential morbidity and mortality.<\/jats:p>\n               <jats:p>We discuss the various aspects of evaluating suspected drug-induced liver injury, combining clinical assessment with the use of diagnostic tools such as Roussel Uclaf Causality Assessment Method to aid in identifying the offending agent.<\/jats:p>","DOI":"10.1136\/bcr-2025-265183","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:00:46Z","timestamp":1756990846000},"page":"e265183","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Progestin-induced liver injury in an asymptomatic patient"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8273-204X","authenticated-orcid":false,"given":"Tarini Prasad","family":"Dandasena","sequence":"first","affiliation":[{"name":"Department of Medical Gastroenterology, All India Institute of Medical Science - Bhopal, Bhopal, MP, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaibhav","family":"Ingle","sequence":"additional","affiliation":[{"name":"General Medicine, All India Institute of Medical Science - Bhopal, Bhopal, MP, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Sukumar","sequence":"additional","affiliation":[{"name":"General Medicine, All India Institute of Medical Science Bhopal, Bhopal, MP, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya Prakash","family":"Meena","sequence":"additional","affiliation":[{"name":"Medical Gastroenterology, All India Institute of Medical Science Bhopal, Bhopal, MP, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"2025090406004103000_18.9.e265183.1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Progestins . Livertox: clinical and research information on drug-induced liver injury. Bethesda(MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548237\/"},{"key":"2025090406004103000_18.9.e265183.2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.115.098822"},{"key":"2025090406004103000_18.9.e265183.3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3748\/wjg.14.38","article-title":"Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump","volume":"14","author":"Meier","year":"2008","journal-title":"WJG"},{"key":"2025090406004103000_18.9.e265183.4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/GRF.0000000000000495","article-title":"Intrahepatic Cholestasis of Pregnancy","volume":"63","author":"Smith","year":"2020","journal-title":"Clin Obstet Gynecol"},{"key":"2025090406004103000_18.9.e265183.5","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000346"},{"key":"2025090406004103000_18.9.e265183.6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00404-020-05456-y","article-title":"Intrahepatic cholestasis of pregnancy as a risk factor for preeclampsia","volume":"301","author":"Mor","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"2025090406004103000_18.9.e265183.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2018.10.041"},{"key":"2025090406004103000_18.9.e265183.8","unstructured":"Fu S , Wu D , Jiang W , et al . Molecular biomarkers in drug-induced liver injury: challenges and future perspectives. Front Pharmacol 2022;13. doi:10.3389\/fphar.2022.123456"},{"key":"2025090406004103000_18.9.e265183.9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025090406004103000_18.9.e265183.10","first-page":"313","article-title":"Real-world Safety and Effectiveness Analysis of Norethisterone in the Management of Abnormal Uterine Bleeding","volume":"14","author":"Jaiswal","year":"2022","journal-title":"J South Asian Fed Obstet Gynecol"},{"key":"2025090406004103000_18.9.e265183.11","doi-asserted-by":"crossref","unstructured":"Chitturi S , Farrell GC . Drug-induced liver disease. In: Schiff ER , Maddrey WC , Sorrell MF , eds. Schiff\u2019s diseases of the liver. England: John Wiley & Sons Ltd, 2012: 703\u201383.","DOI":"10.1002\/9781119950509.ch27"},{"key":"2025090406004103000_18.9.e265183.12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(75)91617-7","article-title":"Letter: Jaundice associated with norethisterone-acetate treatment of breast cancer","volume":"1","author":"Langlands","year":"1975","journal-title":"Lancet"},{"key":"2025090406004103000_18.9.e265183.13","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci031"},{"key":"2025090406004103000_18.9.e265183.14","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-244254","article-title":"Rare case of obstetric cholestasis presenting in the first trimester following in vitro fertilisation","volume":"14","author":"Koh","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025090406004103000_18.9.e265183.15","doi-asserted-by":"crossref","unstructured":"Moussaoui S , Abdelwahed M , Ben Chaaben N , et al . Norethisterone\u2010induced cholestasis: A case report. Clin Case Rep 2022;10. doi:10.1002\/ccr3.5522","DOI":"10.1002\/ccr3.5522"},{"key":"2025090406004103000_18.9.e265183.16","doi-asserted-by":"crossref","unstructured":"Arafa EA , Dhayabaran V , Omar NE , et al . Rare case of norethisterone\u2010induced hepatitis: A case report. Clin Case Rep 2022;10. doi:10.1002\/ccr3.5687","DOI":"10.1002\/ccr3.5687"},{"key":"2025090406004103000_18.9.e265183.17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jceh.2017.01.001","article-title":"Norethisterone Related Drug Induced Liver Injury: A Series of 3 Cases","volume":"7","author":"Choudhary","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"2025090406004103000_18.9.e265183.18","unstructured":"Levin ER , Vitek WS , Hammes SR . Estrogens, progestins, and the female reproductive tract. In: Brunton LL , Hilal-Dandan R , Knollmann BC , eds. Goodman & Gilman\u2019s: the pharmacological basis of therapeutics. 13th edn. McGraw-Hill Education, 2017: 1\u201353."},{"key":"2025090406004103000_18.9.e265183.19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26055"},{"key":"2025090406004103000_18.9.e265183.20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.072140"},{"key":"2025090406004103000_18.9.e265183.21","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfr326"},{"key":"2025090406004103000_18.9.e265183.22","doi-asserted-by":"publisher","DOI":"10.1210\/er.2012-1008"},{"key":"2025090406004103000_18.9.e265183.23","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200210000-00013"},{"key":"2025090406004103000_18.9.e265183.24","doi-asserted-by":"crossref","unstructured":"Xu L , Yuan Y , Che Z , et al . The Hepatoprotective and Hepatotoxic Roles of Sex and Sex-Related Hormones. Front Immunol 2022;13. doi:10.3389\/fimmu.2022.939631","DOI":"10.3389\/fimmu.2022.939631"},{"key":"2025090406004103000_18.9.e265183.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.037"},{"key":"2025090406004103000_18.9.e265183.26","unstructured":"U.S. Food and Drug Administration . Guidance for industry: drug-induced liver injury - premarketing clinical evaluation. Available: http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM174090.pdf"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-265183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:00:49Z","timestamp":1756990849000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-265183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,4]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bcr-2025-265183"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-265183","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}